Brainsway (NASDAQ:BWAY) Upgraded by Wall Street Zen to "Buy" Rating

Key Points

• Brainsway has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, reflecting positive investor sentiment.
• The company reported $0.10 earnings per share, surpassing analyst expectations of $0.07, indicating strong quarterly performance.
• Shares of Brainsway opened at $12.98 on Friday, with a recent 52-week high of $13.65, suggesting strong market interest and growth potential.

Brainsway (NASDAQ:BWAY - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Sunday.

Several other equities research analysts also recently issued reports on the stock. Northland Securities lifted their price target on shares of Brainsway from $15.00 to $19.00 and gave the stock an "outperform" rating in a research note on Thursday, August 14th. HC Wainwright raised their price objective on shares of Brainsway from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $18.00.

Brainsway Trading Up 1.5%

Shares of BWAY traded up $0.22 during mid-day trading on Friday, reaching $14.99. The company had a trading volume of 115,928 shares, compared to its average volume of 62,192. The stock has a market cap of $283.31 million, a price-to-earnings ratio of 57.66 and a beta of 1.42. The firm has a fifty day simple moving average of $12.35 and a 200-day simple moving average of $10.65. Brainsway has a fifty-two week low of $7.06 and a fifty-two week high of $15.10.

Brainsway (NASDAQ:BWAY - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The business had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Brainsway will post 0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new position in Brainsway during the 4th quarter valued at about $44,000. Raymond James Financial Inc. bought a new stake in shares of Brainsway during the 2nd quarter worth about $85,000. GAMMA Investing LLC raised its position in shares of Brainsway by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock worth $89,000 after buying an additional 8,216 shares in the last quarter. Palumbo Wealth Management LLC bought a new stake in shares of Brainsway during the 1st quarter worth about $111,000. Finally, Trexquant Investment LP bought a new stake in shares of Brainsway during the 1st quarter worth about $129,000. 30.11% of the stock is owned by institutional investors and hedge funds.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.